Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902170 | 0.85 | F2 (0.48) | PRSS1F2PRSS2PRSS3 | |
| SCHEMBL34433796 | 0.85 | F2 (0.48) | PRSS1F2PRSS2PRSS3 | |
| SCHEMBL23566125 | 0.84 | PRSS1 (0.62) | PRSS1F2MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23235840 | 0.83 | PRSS1 (0.63) | PRSS1F2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL34433872 | 0.81 | PRSS1 (0.50) | PRSS1F2PRSS2PRSS3F10 | |
| SCHEMBL23901925 | 0.81 | PRSS1 (0.50) | PRSS1F2PRSS2PRSS3F10 | |
| Hydrochloric Acid SCHEMBL23235792 | 0.80 | PRSS1 (0.51) | PRSS1F2PRSS2PRSS3F10 | |
| SCHEMBL23901893 | 0.77 | PRSS1 (0.52) | PRSS1F2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23902317 | 0.77 | PRSS1 (0.46) | PRSS1F2MEN1KMT2APRSS2 | |
| Hydrochloric Acid SCHEMBL23880725 | 0.76 | PRSS1 (0.53) | PRSS1F2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | PRSS1 652/4885F2 1488/4885MEN1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.